Apollomics (APLM) vs Gossamer Bio (GOSS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Apollomics (APLM) has outperformed Gossamer Bio (GOSS) over the past year, gaining 16.6% versus a loss of 94.9%. Apollomics is the larger company by market cap ($61.9 million vs $61.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APLM | GOSS |
|---|---|---|
| Share price | $21.25 | $10.01 |
| Market cap | $61.95M | $61.23M |
| 1-day change | -1.16% | -1.67% |
| YTD return | +15.00% | -95.90% |
| 1-year return | +16.64% | -94.91% |
| 5-year return | — | -99.10% |
| EPS (TTM) | $-7.57 | $-52.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.12 | $309.60 |
| 52-week low | $10.01 | $9.12 |
| Distance from 52-week high | -49.55% | -96.77% |
| Average volume | 21.61K | 377.00K |
| Shares outstanding | 2.91M | 6.12M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- APLM has outperformed GOSS by 111.5 percentage points over the past year.
APLM vs GOSS FAQ
Which is bigger, Apollomics or Gossamer Bio?
Apollomics (APLM) is larger, with a market capitalization of $61.95M compared with $61.23M for Gossamer Bio (GOSS).
Which stock has performed better over the past year, APLM or GOSS?
APLM returned +16.64% over the past 12 months, compared with -94.91% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Apollomics and Gossamer Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.